CANNABICS PHARMACEUTICALS INC. (OTCMKTS:CNBX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0
CANNABICS PHARMACEUTICALS INC. (OTCMKTS:CNBX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

CANNABICS PHARMACEUTICALS INC. (OTCMKTS:CNBX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

On June 21st, 2019, the Board of Directors of the Corporation nominated two Independent Directors to its Board. The Independent Directors shall each be compensated with 125,000 Warrants, at a strike price of $.30. Said Warrants shall have a one-year life.

Dr. Estery Giloz-Ran, 45, has held the position of visiting Scholar at the Stern School of Business at New York University, Visiting Professor in the School of Business at the Yeshiva University, former Head of Accountancy at the Peres Academic Center’s School of Business, and is currently a Lecturer at the Bar Ilan University in Israel, Department of Economics and Accounting. Dr. Giloz-Ran is an External Director in several public companies including Blue Square Real Estate, Aran R&D, Oversiz, Suny, Kamada and is the Former Chairperson of the Board of Tamir Fishman, a known venture capital fund. Dr. Giloz-Ran is a licensed CPA, holds an MBA in Business Administration from Ben Gurion University, and a PhD in Tax, Accounting & Finance from Ben Gurion University

Eran Ballan 54, brings executive management experience with large public entities in international markets. Mr. Ballan served as Partner, and Head of the Biotech Department at Naschitz Brandeis, one of the largest law firms in Israel. Mr. Ballan served as Senior Executive Vice President and General Counsel at Gazit Globe, a Tel Aviv public company part of the TA-35 and Real-Estate 15 index in Israel. Mr. Ballan holds an LL. B degree from Essex University, UK, and an LL.M degree from New York University Faculty of Law.

Item 9.01 – FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

The following Exhibits are filed as part of this Current Report.

 


Cannabics Pharmaceuticals Inc. Exhibit
EX-10.1 2 cannabics_ex1001.htm BOARD RESOLUTION Exhibit 10.1   THE BOARD OF DIRECTORS   OF   CANNABICS PHARMACEUTICALS INC.     The following is a true copy of the resolution duly adopted by the Board of Directors of this Corporation at a special meeting,…
To view the full exhibit click here

About CANNABICS PHARMACEUTICALS INC. (OTCMKTS:CNBX)

Cannabics Pharmaceuticals Inc., formerly American Mining Company, is a biotechnology pharmaceutical company. The Company is engaged in pharmaceutical development. The Company is focused on development and licensing of cannabinoid-based treatments and therapies. It develops and markets various therapies and biotechnological tools aimed at providing relief from ailments that respond to active ingredients sourced from the cannabis plant. These tools include delivery systems for cannabinoids, personalized medicine therapies and procedures based on cannabis originated compounds, and bioinformatics tools. The Company’s flagship product is CANNABICS SR. CANNABICS SR is a technology for a long acting oil capsule that provides administration of cannabis. CANNABICS SR is composed solely from food grade materials and delivers effects for over 10 to 12 hours. The delivery method enables a once per day dosing regimen of medical cannabis to patients. It has not generated revenues.